Maynard Um
-
-
-
-
-
-
-
Moleculin's Annamycin shows promise in pancreatic cancer preclinical study
-
-
-
-
-
-
-
Moleculin expects first pivotal trial data readout in Q1 2026
-
-
-
-
-
-
-
Moleculin presents liver cancer data for Annamycin drug candidate
-
-
-
-
-
-
-
Moleculin Biotech (MBRX) reports efficacy results from Annamycin phase 1B/2 trial
-
-
-
-
-
-
-
Moleculin Biotech (MBRX) PT Lowered to $8 at H.C. Wainwright
-
-
-
-
-
-
-
Moleculin Biotech (MBRX) Prices 2.47M Share and Warrant Offering at $2.23/sh
-
-
-
-
426,820 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

